[1] University of Bordeaux, Bordeaux, France;Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, CNRS UMR 5287, Talence Cedex, France;Faculté de Médecine, Laboratoire INSERM, UMR 894- Université Paris Descartes, Sorbonne Paris Cité, Paris, France;Department for Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany
The inhibition of the Histone Deacetylase 6 (HDAC6) increases tubulin acetylation, thus stimulating intracellular vesicle trafficking and brain-derived neurotrophic factor (BDNF) release, that is, cellular processes markedly reduced in Huntington's disease (HD).
Methods
We therefore tested that reducing HDAC6 levels by genetic manipulation would attenuate early cognitive and behavioral deficits in R6/1 mice, a mouse model which develops progressive HD-related phenotypes.
Results
In contrast to our initial hypothesis, the genetic deletion of HDAC6 did not reduce the weight loss or the deficits in cognitive abilities and nest-building behavior shown by R6/1 mice, and even worsened their social impairments, hypolocomotion in the Y-maze, and reduced ultrasonic vocalizations.
Conclusions
These results weaken the validity of HDAC6 reduction as a possible therapeutic strategy for HD. The data are discussed in terms of additional cellular consequences and anatomical specificity of HDAC6 that could explain these unexpected effects.